How should a serum potassium of 5.5 mmol/L be managed?

Management of Potassium 5.5 mmol/L

A potassium of 5.5 mmol/L requires immediate assessment for ECG changes and symptoms, followed by identification and correction of reversible precipitating factors—do NOT discontinue RAASi therapy if the patient is on it, as this worsens mortality outcomes. 1

Initial Assessment and Risk Stratification

At K+ 5.5 mmol/L, you are at the threshold for hyperkalemia 1. Your immediate actions depend on clinical context rather than the number alone:

Check for Acute Emergency Features

• Obtain ECG immediately - Look for peaked T waves, widened QRS, or any conduction abnormalities 1, 2
• Assess for symptoms - Muscle weakness, paralysis, palpitations 3, 2
• If ECG changes OR symptoms present: This is an emergency requiring acute treatment (see below)
• If asymptomatic with normal ECG: Proceed to identify reversible causes

Critical Pitfall: Pseudohyperkalemia

Before treating, rule out pseudohyperkalemia from hemolysis, repeated fist clenching during phlebotomy, or prolonged tourniquet time 1. Plasma K+ runs 0.1-0.4 mmol/L lower than serum 1, 4. If the sample quality is questionable, repeat the measurement before aggressive intervention.

Management Algorithm

If Asymptomatic with Normal ECG (Most Common Scenario)

Step 1: Identify and Correct Reversible Factors 5, 1

• Review medications: NSAIDs, potassium-sparing diuretics, excessive potassium supplements, trimethoprim
• Assess for constipation (reduces GI potassium elimination)
• Check for metabolic acidosis (shifts K+ extracellularly)
• Evaluate dietary potassium intake, though do not reflexively restrict potassium-rich foods as the evidence linking dietary intake to serum levels is limited and potassium-rich diets have cardiovascular benefits 1

Step 2: Preserve Disease-Modifying Therapy 5, 1 This is critical: Discontinuing RAASi therapy increases mortality and cardiovascular events 1. A 2021 cohort study showed that stopping RAASi when eGFR declined below 30 mL/min/1.73m² was associated with higher mortality compared to continuation 1.

Step 3: Initiate Treatment to Prevent Recurrence 5 Since you have no acute reversible factor and K+ is at 5.5 mmol/L:

• Consider newer potassium binders: Sodium zirconium cyclosilicate (SZC) or patiromer 5, 3, 2

  • These have demonstrated efficacy in maintaining normokalemia for at least one year 5
  • They allow continuation of RAASi therapy 5, 1
  • Real-world data shows 24.6% uptake of SZC and 10.9% of patiromer post-hyperkalemia event 6

• Avoid sodium polystyrene sulfonate (SPS/Kayexalate): Associated with serious GI adverse effects and questionable efficacy 3, 2

• Optimize diuretics if patient has volume overload and preserved renal function 1

• Consider sodium bicarbonate only if metabolic acidosis is present 1

Step 4: Monitor Closely

• Recheck potassium within 1 week 1
• 43.8% of patients experience recurrence, with higher rates (49.1%) if eGFR <30 mL/min 6

If Symptomatic OR ECG Changes Present (Emergency)

Immediate acute treatment sequence 1, 2:

1. IV Calcium (10 mL of 10% calcium gluconate or calcium chloride)

   • Stabilizes cardiac membrane within 1-3 minutes
   • Does NOT lower potassium
   • Primary indication: ECG changes or K+ ≥6.5 mmol/L 2

2. Shift Potassium Intracellularly (works in 30-60 minutes):

   • IV insulin/glucose: 10 units regular insulin + 50 mL dextrose 1

     • Major pitfall: High risk of subsequent hypoglycemia, especially in non-diabetics with low baseline glucose 2
     • Monitor glucose closely for hours after administration

   • Nebulized salbutamol: 20 mg in 4 mL 1

     • Provides synergistic effect with insulin 2
     • Short duration (2-4 hours) 1

3. Remove Potassium from Body:

   • Diuretics if hypervolemic and non-oliguric 1
   • Hemodialysis if oliguric, ESRD, or refractory hyperkalemia 1, 2
   • Consider newer K+ binders (SZC, patiromer) even acutely 3, 2

4. Sodium bicarbonate ONLY if metabolic acidosis present 1

Long-Term Strategy

The most recent 2025 European Heart Journal guidelines emphasize that recurrent hyperkalemia affects 20-43% of patients and requires a proactive prevention plan 5, 6. The key principle: maintain life-saving RAASi therapy while managing potassium 5.

Evidence on RAASi Continuation

Down-titration or discontinuation of RAASi should be discouraged 5. The mortality benefit of continuing RAASi outweighs hyperkalemia risk when potassium is actively managed with binders, SGLT2 inhibitors, or neprilysin inhibitors 5.

Recurrence Risk Factors 5, 6

• eGFR <30 mL/min/1.73m² (49.1% recurrence vs 38.8% with higher eGFR)
• Recurrent hyperkalemia associated with faster eGFR decline (-2.4 mL/min/year)
• Though causality between recurrence and renal decline remains unclear 6

Your approach at K+ 5.5 mmol/L: Assess urgency with ECG and symptoms, correct reversible factors, initiate potassium binders if needed to prevent recurrence, and above all, preserve RAASi therapy if indicated for the patient's underlying condition.